Evidence map›Paper›PMID 30009604›Full record

ArticleOrganic letters2018

Synthesis of ( S)-3-Amino-4-(difluoromethylenyl)-cyclopent-1-ene-1-carboxylic Acid (OV329), a Potent Inactivator of γ-Aminobutyric Acid Aminotransferase.

Matthew J Moschitto, Richard B Silverman

Abstract read
In one paragraph

Article in Organic letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. A newly designed GABA-AT inactivator, (bioRxiv : the preprint server for biology · 2025
    Article
  2. Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Rational Design, Synthesis, and Mechanism of (3Journal of the American Chemical Society · 2022
    Article
  5. Article
  6. Remarkable and Unexpected Mechanism for (Journal of the American Chemical Society · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Matthew J MoschittoDepartments of Chemistry and Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics , Northwestern University , Evanston , Illinois 60208 , United States.
Richard B SilvermanDepartments of Chemistry and Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics , Northwestern University , Evanston , Illinois 60208 , United States.ORCID 0000-0001-9034-1084
Northwestern University · US

Funding

New Inactivators of GABA Aminotransferase for Addiction and EpilepsyR01DA030604 · NIDA · NORTHWESTERN UNIVERSITY · PI SILVERMAN, RICHARD B · 2011 to 2020
$4.0M
NIDA NIH HHS R01 DA030604
6 · The paper itself

Abstract

( S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (OV329, 1) is being developed for the treatment of epilepsy and addiction. The previous 14-step synthesis of OV329 was low yielding, involved an unselective α-elimination to form the cyclopentene, required the use of tert-butyllithium, and produced toxic selenium byproducts in the penultimate step. A new synthesis, which avoids the aforementioned issues, was carried out on large scale, reducing the step count from 14 to 9 steps and increasing the overall yield from 3.7% to 8.1%.

Indexed as

4-Aminobutyrate TransaminaseCyclopentanesEnzyme InhibitorsMolecular StructureOrganometallic CompoundsPhenylacetatesSelenium CompoundsStereoisomerismStructure-Activity RelationshipTransaminases4-Aminobutyrate TransaminasebutyllithiumcyclodrineCyclopentanesEnzyme InhibitorsOrganometallic CompoundsPhenylacetatesSelenium CompoundsTransaminases

Identifiers

PMID30009604
PMCPMC6262895
OpenAlexW2883310288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.